A peer-reviewed study circulated by the Journal of the American Medical Association on Monday, May 22, 2023, took a closer look at study results first released in Sept., testing Pfizer’s experimental drug danuglipron. The study enrolled 411 adult participants with type 2 diabetes. Over 16 weeks, patients who took a high dose of Pfizer’s new … Continue reading Pfizer’s Danuglipron Enters the GLP-1 Weight-Loss Race